NR1H4 and liver disorder: Several studies utilizing mouse models of different liver diseases have assessed the effectiveness of FXR agonism at decreasing hepatic inflammation and shed light on additional anti-inflammatory mechanisms, in addition to negative regulation of NF-κB and NLRP3 (Fig. 3).